Novocure Ltd (NVCR)

[Yankeeipo]

This stock should increase its market cap by at least 3 to 4 times over the next year. The Optune product has been approved for primary glioblastoma and the company already has built a sales force and trained numerous oncologists in the world's major cancer centers. The approval 10 days ago means these doctors must use it with the chemo or risk being sued. The results from its trials were stunning! The procedure is covered by all private insurers and shortly by cms. The company nets $14,000 per month per patient and the average patient will be on it for 2 yrs. assume that Half the patients get the treatment annually in 3 yrs that means at least 12000 patients will be using it in the us alone $168 million per month or over $ 2 billion just for the U.S. alone double it since it is approved in Europe and Japan. By the way it is also approved for non small cell lung cancer in Europe. With the great results the procedure shows with no side effects it will grow rapidly. They have great patent position, no need to share marketing and as a result Hugh profitability for many years which means a monster p/e multiple. The company is also totally unknown. Next Monday's conference is it coming out party. Stock is going much much higher.